{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-26-000004","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.096505+00:00","generated_at":"2026-05-16T10:54:51.083213+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV","bullets":["Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.","2026 guidance: global net sales $630M-$650M; positive cash flow from operations in 2025.","LIVMARLI 2025 sales ~$359M (US $243M, +69% YoY); CHOLBAM/CTEXLI ~$161M (+31% YoY).","Proposed acquisition of Bluejay Therapeutics (brelovitug for HDV) expected close late Jan 2026; $268.5M private placements.","Pipeline: volixibat PSC topline Q2 2026; LIVMARLI EXPAND topline Q4 2026; HDV AZURE data H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-26-000004","json":"https://secwatch.observer/filing/0001759425-26-000004.json","markdown":"https://secwatch.observer/filing/0001759425-26-000004.md","text":"https://secwatch.observer/filing/0001759425-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/0001759425-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirm-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:51.083213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}